WB result of Invivo anti-mouse 4-1BB (CD137) Recombinant mAb
Primary antibody: Invivo anti-mouse 4-1BB (CD137) Recombinant mAb at 1/1000 dilution
Lane 1: 4-1BB/TNFRSF9 His Tag Protein, Mouse 10 ng
Lane 2: 4-1BB/TNFRSF9 His Tag Protein, Rat 2 µg
Lane 3: 4-1BB/TNFRSF9 His Tag Protein, Human 2 µg
Secondary antibody: Goat Anti-rat IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 28 kDa
Observed MW: 25-35 kDa
Product Details
Product Details
Product Specification
Host | Rat |
Antigen | 4-1BB (CD137) |
Synonyms | Tumor necrosis factor receptor superfamily member 9; 4-1BB ligand receptor; T-cell antigen 4-1BB; Ila; Ly63; Tnfrsf9 |
Location | Cell membrane |
Accession | P20334 |
Antibody Type | Recombinant mAb |
Application | in vivo 4-1BB stimulation, in vitro 4-1BB stimulation |
Reactivity | Ms |
Purification | Protein A |
Concentration | 5 mg/ml |
Purity | >95% Determined by SEC-HPLC |
Endotoxin | <2EU/mg |
Conjugation | Unconjugated |
Physical Appearance | Liquid |
Storage Buffer | PBS pH7.4 |
Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
application | dilution | species |
WB | 1:1000 | Ms |
Background
4-1BB (CD137, TNFRSF9) is a 39 kDa inducible costimulatory receptor expressed on activated T, NK, NKT and dendritic cells that, upon engagement by its trimeric ligand 4-1BBL or agonistic antibodies, recruits TRAF1/2 to trigger NF-κB, MAPK and PI3K–Akt signaling cascades, thereby enhancing proliferation, survival, cytokine production and cytotoxicity of CD8⁺ and CD4⁺ T cells and NK cells; its expression is tightly regulated (peaking 24–72 h post-activation and restrained by PD-1/CTLA-4 pathways) and its therapeutic agonism is exploited in immuno-oncology to overcome tumor-induced exhaustion, while antagonists are explored for autoimmune diseases.
Picture
Picture
Western Blot
